logo
Researchers discover incredible new method to squeeze water out of crystals: 'Presents a new approach'

Researchers discover incredible new method to squeeze water out of crystals: 'Presents a new approach'

Yahoo15 hours ago

Scientists in Japan are excited about a new process that can deliver clean water.
In a study published in the Journal of Materials Chemistry A, University of Tsukuba researchers discussed a new water production possibility involving the application of pressure to copper-chromium Prussian blue analog, a kind of crystalline compound.
Since the material is full of pores, the scientists discovered that applying pressure — much like you would a wet sponge — can expel the water retained inside.
To exert pressure, the researchers experimented with infrared spectroscopy, X-ray absorption, and fluorescence spectroscopy in order to alter the electrical state of the water and the copper within the crystal.
Due to the resulting pressure, the crystalline pores became hydrophobic, thereby making them capable of releasing stored water.
According to the study, 1 kilogram of the crystal could yield about 240 grams of water in the form of droplets.
"[The research] presents a new approach to water production, which is an important step towards the further development of the water environmental improvement technology," the team explained.
With planetary temperatures on the rise, water pollution at an all-time high, and water shortages on the horizon for the coming decades, developing new means to source water is becoming increasingly essential, both for human civilizations and for the environment as a whole.
An estimated 4.4 billion individuals now lack adequate access to safe drinking water across 135 low- and middle-income nations, based on a 2024 report published in the journal Science.
Implementing new potable water generation options can help ensure the health and safety of entire populations who may be struggling in more arid or water-deficient environments, in addition to cutting down on water bills for consumers everywhere.
How often do you worry about the quality of your drinking water?
Never
Sometimes
Often
Always
Click your choice to see results and speak your mind.
The University detailed that the achievement can lead to the "advancement of pressure-induced onsite water production technologies" to use in harsh environments, and offer a new insight into water resource processes.
Meanwhile, circulating water back into nature can work wonders for our planetary health, helping to nurture ecosystems and boost biodiversity.
Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

RevolKa Ltd. Joins Research and Development Program for Innovative Biologics Funded by the Japanese Agency for Medical Research and Development (AMED)
RevolKa Ltd. Joins Research and Development Program for Innovative Biologics Funded by the Japanese Agency for Medical Research and Development (AMED)

Yahoo

time2 hours ago

  • Yahoo

RevolKa Ltd. Joins Research and Development Program for Innovative Biologics Funded by the Japanese Agency for Medical Research and Development (AMED)

RevolKa Fueling Up AI Protein Engineering Platform-based Therapeutic Program SENDAI, Japan, June 30, 2025--(BUSINESS WIRE)--RevolKa Ltd. (RevolKa), a venture-backed biotech company providing a cutting-edge AI-driven protein engineering technology platform, called aiProtein® has announced its participation in a research and development program funded by a government grant of 54 million JPY (approximately US$372K for the first year) from the Japanese Agency for Medical Research and Development (AMED). This project, set to continue over 4 years, is led by Prof. Mitsuo Umetsu of Tohoku University, who also serves as RevolKa's Chief Scientific Officer. This opportunity will further accelerate RevolKa's rare disease drug discovery and development efforts, previously announced on July 30th, 2024. ( core technology, aiProtein®: a robust directed protein evolution platform integrated with AI (artificial intelligence) creates exceptionally high performance proteins, going beyond natural evolution and offering advantages for therapeutic strategies. aiProtein® has generated many successful outcomes with many partner companies. About aiProtein® TechnologyRevolKa's proprietary technology, aiProtein® is an AI-assisted directed evolution platform for proteins. Naturally occurring proteins are linear polymers composed of amino acids and their derivatives, folding into a tertiary structure through internal complex atomic interactions to exhibit biological functions. Proteins have evolved their biological functional complexity over hundreds of millions of years. However, the relationship between protein sequence, structure, and function remains poorly understood to enable rational design of protein sequences for specific function. RevolKa's AI engine is trained with sequence-function relationship data, enabling statistical prediction of optimized protein sequences with desired functions. Furthermore, aiProtein® can evolve multiple properties simultaneously. This technology is a powerful and cost-effective solution for creating novel and highly functional proteins suitable for pharmaceutical and industrial applications. About RevolKa is a venture-backed biotechnology company founded in April 2021 by academic and industry experts in biotechnology and artificial intelligence. Our mission is to contribute to human well-being by creating novel proteins for therapeutics and industrial applications using our proprietary technology, aiProtein®. The name "RevolKa" is derived from the Latin word for evolution, "evolutio" and the Ainu (an indigenous Japanese people) word for raise, "reska". RevolKa's headquarters and laboratories are located in Sendai, Japan. The company's investors include D3 LLC, Tohoku University Venture Partners Co., Ltd., DEEPCORE Inc., and SBI Investment Co., Ltd. For more information, visit View source version on Contacts RevolKa IwaseEmail: info@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Korea's InnoCORE Attracts Top Global Postdocs Through U.S. Job Fairs
Korea's InnoCORE Attracts Top Global Postdocs Through U.S. Job Fairs

Yahoo

time2 hours ago

  • Yahoo

Korea's InnoCORE Attracts Top Global Postdocs Through U.S. Job Fairs

Over 100 postdoctoral researchers from top global universities were interviewed, underscoring Korea's rising global research appeal. SEOUL, South Korea, June 30, 2025 /PRNewswire/ -- Korea has launched its first large-scale initiative to attract outstanding global researchers in science and technology through InnoCORE, a new fellowship program aimed at recruiting international talent in Artificial Intelligence and Science & Technology (AI+S&T). The Ministry of Science and ICT of the Republic of Korea, in collaboration with the country's four Institutes of Science and Technology (KAIST, GIST, DGIST, and UNIST), will invest KRW 300 billion (approximately USD 225 million) over the next five years to recruit and support 400 postdoctoral researchers in the interdisciplinary field of AI+S&T. As part of its global outreach efforts, InnoCORE hosted in-person job fairs in Boston (June 18, Northeastern University), New York (June 20, NYU-KAIST Global Campus), and Silicon Valley (June 23, KIC Silicon Valley). More than 100 postdoctoral researchers conducted face-to-face interviews with Korean research group leaders at these job fairs. The job fair not only attracted participants from local institutions—such as Harvard, MIT, NYU, Columbia, UC Berkeley, and Stanford—but also from other premier universities across the United States, including Cornell University, the University of Chicago, and the University of Florida. The strong turnout of students reflects a growing interest in Korea's evolving role as a global research hub. Professor Hee-Seung Lee, Research Group leader of the AI Co-Research & Education for Innovative Drug Institute at KAIST, noted: "We had the chance to meet highly capable and motivated researchers with a strong potential to lead groundbreaking work in AI+S&T and was able to hear firsthand their enthusiasm for such a unique opportunity. Korea's strategic efforts through InnoCORE are resonating internationally. If these talented researchers enter our network, it will not only elevate Korea's global scientific standing but also strengthen our global talent pipeline in the future." Dr. Hyojun Lim, a postdoctoral fellow at MIT who participated in the job fair, commented: "For U.S.-based researchers seeking career opportunities in Korea, InnoCORE provided a truly practical and insightful platform. Direct discussions with the lead professors of the research projects gave me a clear sense of each research group's mission and future direction—far beyond what a website or brochure can convey." Building on the success of these events, the Ministry of Science and ICT of the Republic of Korea will officially commence the selection and onboarding of fellows in July. Each selected postdoctoral researcher will be offered a competitive base annual salary of KRW 90 million (~USD 66,000), with opportunities for additional research funding and compensation available through partnerships with industry and academic institutions. Fellows will also have access to advanced research infrastructure, including supercomputers, semiconductor cleanrooms, and cutting-edge biomedical facilities. The program will also implement a multi-layered mentoring system involving academic advisors, industry experts, and international researchers—designed to strengthen both independent research and multinational cooperation capabilities. InnoCORE currently operates through eight interdisciplinary research clusters. The projects are run in collaboration with Korea's top, major industry leaders (Samsung, LG, Hyundai, Naver), and global research giants such as MIT, Stanford, Harvard, Oxford, Meta, Google, and IBM Research. Research areas include large language models (LLMs), generative AI, AI-based drug discovery, advanced manufacturing, aerospace AI, clean energy, and nanotechnology for brain disease diagnostics. Mr. Chang-yoon Lee, first vice minister of Ministry of Science and ICT of the Republic of Korea stated: "The InnoCORE Global Postdoctoral Job Fair showed that Korea is emerging as an attractive destination for the world's top scientific talent. We will continue to invest in building an open, globally connected research ecosystem—one where talent from around the world can grow, collaborate, and lead globally impactful science from Korea." Press Contact 2025 InnoCORE Global Postdoctoral Job Fair Secretariat View original content to download multimedia: SOURCE KAIST Sign in to access your portfolio

Tool Predicts if Seniors with Cancer Can Stay Home Post Op
Tool Predicts if Seniors with Cancer Can Stay Home Post Op

Medscape

time3 hours ago

  • Medscape

Tool Predicts if Seniors with Cancer Can Stay Home Post Op

TOPLINE: A novel predictive model named STAYHOME effectively estimated the risk of losing the ability to live at home among older adults after cancer surgery, demonstrating good calibration with minimal deviation from observed risks. The model predicted a 2.4% and 3.4% risk for admission to a nursing home at 6 months and 12 months, respectively. METHODOLOGY: Older adults prioritize long-term functional independence, and the ability to return and stay at home after cancer surgery remains a key concern. However, current prognostic tools focus on short-term outcomes, lacking individualized long-term risk estimates. To estimate the risk of losing the ability to live at home post-surgery, researchers developed and internally validated a risk prediction model, named STAYHOME, among 97,353 community-dwelling older adults (median age, 76 years) who underwent cancer surgery between 2007 and 2019. The predictive model included preoperative variables such as age, sex, rural residence, previous cancer diagnosis, surgery type, frailty, receipt of home care support, receipt of neoadjuvant therapy, cancer site, and cancer stage. The primary outcome was the inability to stay at home after cancer surgery, defined as the time to admission to a nursing home, and was measured at 6 months and 12 months. TAKEAWAY: Overall, 2658 patients (2.7%) at 6 months and 3746 (3.8%) at 12 months were admitted to a nursing home post-surgery. The mean predicted risk of not staying home was 2.4% at 6 months and 3.4% at 12 months. The STAYHOME tool demonstrated a strong predictive capability, with areas under the curve of 0.76 and 0.75 for 6- and 12-month predictions, respectively. The tool also demonstrated minimal deviation from the observed risk for 6-month (0.33 percentage point on average; calibration slope, 1.27) and 12-month (0.46 percentage point on average; calibration slope, 1.17) predictions. The model's calibration was excellent for most predictors at 6 months and 12 months, with a deviation of < 0.8 percentage points from the observed probability; only age older than 85 years (1.13%), preoperative frailty (1.16%), and receipt of preoperative home care support (1.25%) exceeded the deviation of 1 percentage point at 12 months. Across risk deciles, deviations between predicted and observed probabilities were 0.1%-1.5% at 6 months and 0.1%-1.9% at 12 months, reflecting good calibration. The deviation for the slight overestimation at or above the seventh decile remained under 2% for both timepoints. IN PRACTICE: 'The STAYHOME tool demonstrated good discrimination and was well calibrated. Thus, it may be a useful tool to identify a specific group of individuals at risk of not remaining home,' the authors wrote. '[The tool] used information readily available to patients, care partners, and healthcare professionals and may be implemented to provide them with individualized risk estimates and improve surgical oncology care delivery and experience for older adults,' they concluded. SOURCE: This study, led by Julie Hallet, MD, Odette Cancer Centre, Sunnybrook Health Sciences Centre in Toronto, Ontario, Canada, was published online in JAMA Surgery. LIMITATIONS: The STAYHOME tool showed slightly reduced discrimination for predictor levels of preoperative frailty, preoperative home care use, receipt of neoadjuvant therapy, and having stage IV disease. The model was also less well calibrated at the extremes of the risk distribution, with a slight overestimation in higher-risk categories. DISCLOSURES: This study was funded by operating grants from the Canadian Institutes for Health Research, Ontario Cancer Research Institute, and ICES. One author reported receiving speaker fees from Ipsen, outside the submitted work. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store